PeptideScanner retained ClinicalTrials.gov record NCT02588716 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-27, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00734279 at 2026-11-15T22:03:26.540Z. Its registry update date was 2017-12-26, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02718599 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-12-19, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT01705587 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-12-12, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00433966 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-12-04, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02745470 at 2026-07-30T21:22:00.254Z. Its registry update date was 2017-11-29, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00596934 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01588418 at 2026-07-30T21:22:00.248Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01762943 at 2026-07-30T21:22:00.263Z. Its registry update date was 2017-11-20, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02102204 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-11-17, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT03061604 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-14, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00422058 at 2026-07-30T21:22:00.247Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00781937 at 2026-07-30T21:22:00.250Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01557166 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-11-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT02647944 at 2026-07-30T21:22:00.265Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02351128 at 2026-07-30T21:22:00.252Z. Its registry update date was 2017-10-18, and PeptideScanner's reviewed identity mapping was lanreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00223717 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-10-13, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01402336 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-10-10, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT00589472 at 2026-07-30T21:22:00.251Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01969149 at 2026-07-30T21:22:00.262Z. Its registry update date was 2017-10-06, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00492960 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00620451 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00889473 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT01396213 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-20, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00362856 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00386490 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-12, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00386165 at 2026-11-16T01:45:58.486Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was larazotide.
PeptideScanner retained ClinicalTrials.gov record NCT00456885 at 2026-07-30T21:23:14.762Z. Its registry update date was 2017-09-11, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00295178 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-09-07, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02321878 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-09-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02516150 at 2026-07-30T21:23:14.758Z. Its registry update date was 2017-08-31, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02474914 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-08-22, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01153425 at 2026-07-30T21:23:14.757Z. Its registry update date was 2017-08-04, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01467882 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-07-28, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00978393 at 2026-07-30T21:23:14.756Z. Its registry update date was 2017-07-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01552343 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-07-11, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT02273115 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00600886 at 2026-07-30T21:23:14.761Z. Its registry update date was 2017-07-02, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT02508103 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-06-27, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT02291679 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-06-15, and PeptideScanner's reviewed identity mapping was linaclotide.
PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01679197 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00140231 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-07, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT02125188 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01023061 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-06-06, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02223429 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-06-05, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00225420 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-06-01, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01652573 at 2026-11-15T21:54:02.201Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was calcitonin-salmon.
PeptideScanner retained ClinicalTrials.gov record NCT01562678 at 2026-07-30T21:24:24.231Z. Its registry update date was 2017-05-31, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01431391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-30, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02107391 at 2026-07-30T21:24:24.227Z. Its registry update date was 2017-05-24, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00919802 at 2026-11-16T00:59:19.138Z. Its registry update date was 2017-05-23, and PeptideScanner's reviewed identity mapping was oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT02311231 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-05-19, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00130117 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-05-17, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT00170157 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00759772 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-05-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01637272 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-05-10, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01739049 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-05-04, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01565265 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-05-01, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT02916251 at 2026-11-16T01:42:39.027Z. Its registry update date was 2017-04-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.
PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide.
PeptideScanner retained ClinicalTrials.gov record NCT01134549 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT00672074 at 2026-07-30T21:24:24.228Z. Its registry update date was 2017-04-14, and PeptideScanner's reviewed identity mapping was ipamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01254565 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT02135445 at 2026-11-15T21:52:09.579Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01280344 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-13, and PeptideScanner's reviewed identity mapping was ipamorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01414114 at 2026-11-15T22:07:29.454Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was etelcalcetide.
PeptideScanner retained ClinicalTrials.gov record NCT00182754 at 2026-07-30T21:24:24.234Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00650546 at 2026-07-30T21:24:24.230Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01400516 at 2026-07-30T21:24:24.225Z. Its registry update date was 2017-04-11, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01155180 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01651780 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT01994330 at 2026-11-16T01:33:21.554Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00380406 at 2026-07-30T21:24:24.229Z. Its registry update date was 2017-04-05, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT02022254 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-04-04, and PeptideScanner's reviewed identity mapping was semaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00332969 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-03-31, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01438086 at 2026-11-16T17:35:13.282Z. Its registry update date was 2017-03-30, and PeptideScanner's reviewed identity mapping was mecasermin.
PeptideScanner retained ClinicalTrials.gov record NCT00358579 at 2026-11-15T22:08:31.832Z. Its registry update date was 2017-03-17, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01888120 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-03-16, and PeptideScanner's reviewed identity mapping was ziconotide.
PeptideScanner retained ClinicalTrials.gov record NCT00947752 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-03-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00318461 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-03-07, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01484873 at 2026-07-30T21:25:36.820Z. Its registry update date was 2017-03-03, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00855439 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT03068065 at 2026-07-30T21:25:36.832Z. Its registry update date was 2017-03-01, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01919723 at 2026-11-15T21:59:29.646Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT01518101 at 2026-07-30T21:25:36.782Z. Its registry update date was 2017-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00171886 at 2026-07-30T21:25:36.764Z. Its registry update date was 2017-02-24, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01128894 at 2026-07-30T21:25:36.852Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT02325960 at 2026-07-30T21:25:37.027Z. Its registry update date was 2017-02-23, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00395291 at 2026-11-16T17:28:23.215Z. Its registry update date was 2017-02-20, and PeptideScanner's reviewed identity mapping was mk-677.
PeptideScanner retained ClinicalTrials.gov record NCT00093067 at 2026-11-15T22:01:45.056Z. Its registry update date was 2017-02-13, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT00239993 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT02208986 at 2026-11-15T21:49:16.513Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT02384070 at 2026-11-15T21:58:19.888Z. Its registry update date was 2017-02-03, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00873223 at 2026-07-30T21:25:36.788Z. Its registry update date was 2017-01-26, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01356862 at 2026-11-15T22:05:38.400Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was pasireotide.
PeptideScanner retained ClinicalTrials.gov record NCT01515592 at 2026-07-30T21:25:36.784Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01516255 at 2026-07-30T21:25:36.817Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01518166 at 2026-07-30T21:25:36.824Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01620476 at 2026-07-30T21:25:37.025Z. Its registry update date was 2017-01-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01507272 at 2026-07-30T21:25:36.818Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01507337 at 2026-07-30T21:25:36.779Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01508806 at 2026-07-30T21:25:36.763Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01620463 at 2026-07-30T21:25:36.783Z. Its registry update date was 2017-01-24, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00223691 at 2026-07-30T21:25:36.812Z. Its registry update date was 2017-01-18, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00000325 at 2026-11-16T17:31:07.936Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was gonadorelin.
PeptideScanner retained ClinicalTrials.gov record NCT01457703 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00838916 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00839527 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00849017 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.
PeptideScanner retained ClinicalTrials.gov record NCT00849056 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.